Rocket Lab (NASDAQ: RKLB) has seen its stock price tumble 56% from the year-to-date high of $150 reached in May, currently trading around $65. This sharp decline comes even as the company hits significant operational milestones, prompting investors to question whether this is a buying opportunity or a sign of deeper issues.
Strong fundamentals persist
The space infrastructure company continues to report robust growth. In the second quarter, revenue surged 62% year-over-year to over $234 million, while backlog climbed to more than $2.36 billion. Management projects third-quarter revenue between $250 million and $265 million, with gross margins in the 29%–31% range. Analysts expect full-year revenue to grow 59% to $958 million, followed by $1.36 billion next year—a 42% annual increase.
Recent contract wins with the U.S. Space Force, Viasat, and MDA underscore strong demand. The company also unveiled its next-generation Inverted Metamorphic (IMM) Apex solar cells, which promise higher efficiency and faster production times. President Brad Clevenger highlighted that the product offers a lightweight, germanium-free solution for space applications.
Additionally, Rocket Lab's planned $8 billion acquisition of Iridium is a strategic move to secure valuable L-band spectrum, potentially enabling new services and even a future Starlink competitor. This deal could open up significant market opportunities beyond its core launch and satellite businesses.
Analyst sentiment remains bullish
Despite the stock's slide, Wall Street remains largely optimistic. Berenberg initiated coverage with a Buy rating and a $83 price target. Bank of America's Ronald Epstein sees a target of $110, while Citizens' Trevor Walsh is even more bullish at $130. Other positive calls come from Cantor Fitzgerald, Citigroup, and Craig Hallum. These targets imply substantial upside from current levels.
However, not all analysts are equally enthusiastic. Some caution that the stock's valuation may already reflect much of the good news, and execution risks—such as potential delays in the Neutron rocket program—could weigh on sentiment. As noted in a recent analysis of Rocket Lab's backlog and Neutron delays, the market is sensitive to any hiccups in the company's ambitious roadmap.
Technical picture shows potential reversal
From a technical standpoint, the daily chart reveals that RKLB has fallen below key moving averages (50-day and 100-day), indicating bearish momentum in the short term. However, the Relative Strength Index (RSI) has rebounded to 40, its highest level since late August, suggesting selling pressure may be easing. More importantly, the stock appears to be forming a double-bottom pattern, with a neckline at $86.6 (the high from August 10). A break above this level could signal a trend reversal, with the next target around $100.
This pattern is often viewed as a bullish reversal signal, but it is not foolproof. Investors should watch for a decisive close above the neckline to confirm the setup. Until then, the stock remains in a downtrend, and further downside is possible.
Weighing the opportunity
For long-term investors, the combination of strong revenue growth, a record backlog, and strategic acquisitions paints a promising picture. The recent pullback may offer an attractive entry point, especially if the double-bottom pattern plays out. However, the stock is still highly volatile, and the broader market environment—including interest rate concerns and geopolitical tensions—could impact sentiment. As always, diversification and risk management are key.
Investors might also consider the recent buying activity by Cathie Wood's ARK, which added $44 million in Rocket Lab shares during a nine-session slide, as noted in this report on ARK's move. Such institutional interest could provide some support.
In summary, Rocket Lab's fundamentals remain solid, and the technicals hint at a possible rebound. But whether this is a buying opportunity depends on one's risk tolerance and investment horizon. The stock is not for the faint-hearted, and investors should conduct their own due diligence.
This article is for informational purposes only and does not constitute financial advice.
